摘要
Abstract
AIM:To evaluate the efficacy of intravitreal ranibizumab injection(IVR)combined with subthreshold micropulse(STMP)in the treatment of diabetic macular edema(DME).
METHODS:Retrospective study.A total of 98 DME patients(98 eyes)admitted to our hospital from March 2022 to March 2023 were enrolled and divided into two groups based on treatment methods:the control group(49 eyes)received STMP yellow laser therapy alone,while the study group(49 eyes)underwent combined IVR and STMP yellow laser therapy.Comparisons were made between the two groups regarding best corrected visual acuity(BCVA),retinal neovascularization(RNV)leakage area,parafoveal macular thickness(PMT),foveal macular thickness(FMT),central retinal thickness(CRT),and foveal avascular zone(FAZ)area,quality of life was assessed using the Chinese-version low vision quality of life questionnaire(CLVQOL),and complication rates were recorded.Additionally,serum levels of nitric oxide synthase(NOS)and vascular endothelial growth factor(VEGF)were measured before and after treatment in both groups.
RESULTS:At 3 mo after treatment,both groups showed improved BCVA compared to baseline,with reduced RNV leakage area,PMT,FMT,CRT,FAZ,and serum levels of VEGF,while serum NOS levels and all CLVQOL domain scores were higher than pre-treatment(all P＜0.05).Furthermore,the study group demonstrated superior outcomes in all these parameters compared to the control group(all P＜0.05),and no ocular or systemic complications occurred in any patient.
CONCLUSION:IVR combined with STMP yellow laser for DME improves visual acuity,reduces RNV leakage area,PMT,FMT,CRT,and FAZ,modulates serum NOS and VEGF levels,enhances quality of life,and demonstrates good safety.关键词
玻璃体腔注射雷珠单抗/糖尿病性黄斑水肿/黄斑厚度/一氧化氮合酶/生活质量Key words
intravitreal ranibizumab injection/diabetic macular edema/macular thickness/nitric oxide synthase/quality of life
